论文部分内容阅读
目的观察蚓激酶胶囊治疗不稳定型心绞痛的疗效。方法将不稳定型心绞痛50例门诊患者随机分为两组,其中加服蚓激酶胶囊组28例(观察组),不加服蚓激酶胶囊组22例(对照组),疗程均为14d,两组进行疗效对比。结果观察组临床总有效率及心电图ST、T波改善率分别为89%与79%;对照组临床总有效率依次为72%与64%,两组比较差异有统计学意义(P<0.01)。观察组患者各项指标均较前明显改善,而且明显优于对照组,两组均未发现不良反应。结论蚓激酶胶囊是治疗不稳定型心绞痛安全有效的药物,可以降低血黏度,增加冠状动脉血流量,减少心绞痛的发作。
Objective To observe the efficacy of lumbrokinase capsules in the treatment of unstable angina pectoris. Methods Fifty outpatients with unstable angina pectoris were randomly divided into two groups, including 28 cases treated with lumbrokinase capsules (observation group) and 22 cases treated with lumbrokinase capsules (control group) for 14 days, two Group for efficacy comparison. Results The total effective rate of observation group and ST, T wave electrocardiogram improvement rates were 89% and 79% respectively. The total effective rate of the control group was 72% and 64% respectively, with significant difference between the two groups (P <0.01) . All the indexes in the observation group were significantly improved compared with the previous group, and significantly better than the control group, no adverse reactions were found in both groups. Conclusion Lumbukinase capsule is a safe and effective treatment for unstable angina pectoris, which can reduce blood viscosity, increase coronary blood flow and reduce the incidence of angina pectoris.